DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

predictors of adverse cardiovascular events after acute myocardial
infarction. The protective effects of captopril. Circulation,
1994, 89:68–75.
Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet, 2006,
368:1449–1456.
Stasch JP, Schmidt PM, Nedvetsky PI, et al. Targeting the hemeoxidized
nitric oxide receptor for selective vasodilatation of
diseased blood vessels. J Clin Invest, 2006, 116:2552–2561.
Studies On Left Ventricular Dysfunction (SOLVD) Investigators.
Effect of enalapril on mortality and the development of heart
failure in asymptomatic patients with reduced left ventricular
ejection fractions. N Engl J Med, 1992, 327:685–691.
Swedberg K. Initial experience with β blockers in dilated cardiomyopathy.
Am J Cardiol, 1993, 71:30C–38C.
Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit
on event- free survival and heart failure hospitalization from
fixed- dose combination of isosorbide dinitrate/hydralazine:
Consistency across subgroups in the African- American Heart
Failure Trial. Circulation, 2007, 115:1747–1753.
Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic
effects of tolvaptan, a vasopressin V 2
receptor blocker, in
patients with symptomatic heart failure and systolic dysfunction:
An international, multicenter, randomized, placebocontrolled
trial. J Am Coll Cardiol, 2008, 52:1540–1545.
Uretsky BF, Young JB, Shahidi FE, et al. Randomized study
assessing the effect of digoxin withdrawal in patients with mild
to moderate chronic congestive heart failure: Results of the
PROVED trial. PROVED Investigative Group. J Am Coll
Cardiol, 1993, 22:955–962.
Varin R, Mulder P, Tamion F, et al. Improvement of endothelial
function by chronic angiotensin- converting enzyme inhibition
in heart failure: Role of nitric oxide, prostanoids, oxidant
stress, and bradykinin. Circulation, 2000, 27:351–356.
Villarreal F, ed. Interstitial Fibrosis in Heart Failure. Springer,
New York, 2005.
Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects
of metoprolol in idiopathic dilated cardiomyopathy.
Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study
Group. Lancet, 1993, 342:1441–1446.
Wang W, Chen JS, Zucker IH. Carotid sinus baroreceptor sensitivity
in experimental heart failure. Circulation, 1990,
81:1959–1966.
Weber KT. Efficacy of aldosterone receptor antagonism in heart
failure: Potential mechanisms. Curr Heart Fail Rep, 2004,
1:51–56.
White HD, Aylward PE, Huang Z, et al. Mortality and morbidity
remain high despite captopril and/or Valsartan therapy in
elderly patients with left ventricular systolic dysfunction, heart
failure, or both after acute myocardial infarction: Results from
the Valsartan in Acute Myocardial Infarction Trial
(VALIANT). Circulation, 2005, 112:3391–3399.
Yan C, Ding B, Shishido T, Chang- Hoon Woo C- H, et al.
Activation of extracellular signal- regulated kinase 5 reduces
cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase
3A/inducible cAMP early repressor feedback loop.
Circ Res, 2007, 100:510–519.
Yusuf S, Pfeffer M, Swedberg K, et al. CHARM Investigators
and Committees. Effects of candesartan in patients with
chronic heart failure and preserved left ventricular ejection
fraction: The CHARM- Preserved trial. Lancet, 2003, 362:
777–781.
813
CHAPTER 28
PHARMACOTHERAPY OF CONGESTIVE HEART FAILURE